Robert Berman sold $7.5M worth of shares in Biohaven Pharmaceutical Holding Co., Ltd. in June 2018
Jul 08, 2018
Chief Medical Officer at Biohaven Pharmaceutical Holding Co., Ltd.
In The News
Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
Jul 19, 2019 - PR Newswire
Jul 08, 2018 - RelSci
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
In The News
Aug 09, 2019 - SEC
-Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
Aug 09, 2019 - ENP Newswire
Aug 07, 2019 - PR Newswire